{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:29:42Z","timestamp":1789046982306,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) is a serious but preventable complication after bariatric surgery, most of them after hospital discharge. The optimal regimen and duration of post-discharge prophylaxis, particularly the role of direct oral anticoagulants, remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate 30-day VTE and bleeding event rates in high-risk patients undergoing one-anastomosis gastric bypass who received 15-day enoxaparin, 30-day enoxaparin, or 30-day rivaroxaban prophylaxis, and to perform exploratory comparisons among the regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, open-label, three-arm clinical trial, high-risk adults undergoing laparoscopic OAGB were randomized before discharge (1:1:1) to enoxaparin 40\u00a0mg subcutaneously twice daily for 15 days, enoxaparin 40\u00a0mg twice daily for 30 days, or rivaroxaban 10\u00a0mg orally once daily for 30 days, after standardized in-hospital enoxaparin and early ambulation. Participants underwent clinical assessment and duplex ultrasonography of the lower-limb and porto-mesenteric veins on postoperative days 15 and 30. The primary outcome was objectively confirmed VTE within 30 days. Bleeding was classified as International Society on Thrombosis and Haemostasis (ISTH) major bleeding or clinically relevant non-major bleeding (CRNMB). Because the expected event rate was low and no non-inferiority or equivalence margin was prespecified, comparisons were interpreted as exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 288 patients were randomized to 15-day enoxaparin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200997), 30-day enoxaparin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200997), or 30-day rivaroxaban (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200994). One symptomatic lower-limb deep vein thrombosis occurred in the 15-day enoxaparin group (1.0%; 95% CI, 0.03%\u20135.6%); no VTE events occurred in the 30-day enoxaparin group (0%; 95% CI, 0%\u20133.7%) or the rivaroxaban group (0%; 95% CI, 0%\u20133.8%). Total bleeding occurred in 4\/97 patients (4.1%) in each enoxaparin group and 8\/94 patients (8.5%) in the rivaroxaban group. The absolute difference in total bleeding between rivaroxaban and 30-day enoxaparin was 4.4% points (95% CI, \u2212\u20092.9 to 12.2), indicating substantial imprecision. No porto-mesenteric venous thrombosis was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Only one VTE event occurred, precluding reliable conclusions regarding comparative efficacy or prophylaxis duration. Bleeding estimates were also imprecise and do not establish comparative safety or equivalence between rivaroxaban and enoxaparin. The trial adds descriptive event-rate data from a standardized OAGB pathway, but larger multicenter studies with prespecified comparative hypotheses and assessment of adherence, oral tolerance, and drug exposure are required.<\/jats:p>\n                    <jats:p>The study was approved by the Research Ethics Committee and registered at ClinicalTrials.gov.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11695-026-08882-0","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:14:29Z","timestamp":1786436069000},"page":"4853-4861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extended Venous Thromboembolism Prophylaxis After One-Anastomosis Gastric Bypass: A Three-Arm Randomized Trial of Enoxaparin Duration and Rivaroxaban"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-3610","authenticated-orcid":false,"given":"Mohammed Elshwadfy","family":"Nageeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagy Salah","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkarem Ahmed Abdelkarem","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled Mosleh","family":"Torfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Nasr","family":"Shazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"11","key":"8882_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1007\/s11695-013-1073-1","volume":"23","author":"DA Froehling","year":"2013","unstructured":"Froehling DA, Daniels PR, Mauck KF, Collazo-Clavell ML, Ashrani AA, Sarr MG, Petterson TM, Heit JA. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study. Obes Surg. 2013;23(11):1874\u20139. https:\/\/doi.org\/10.1007\/s11695-013-1073-1.","journal-title":"Obes Surg"},{"issue":"2","key":"8882_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.soard.2010.12.008","volume":"7","author":"DA Winegar","year":"2011","unstructured":"Winegar DA, Sherif B, Pate V, DeMaria EJ. Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2011;7(2):181\u20138. https:\/\/doi.org\/10.1016\/j.soard.2010.12.008.","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"8882_CR3","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s11695-024-07184-7","volume":"34","author":"W El Ansari","year":"2024","unstructured":"El Ansari W, El-Menyar A, El-Ansari K, Al-Ansari A, Lock M. Cumulative incidence of venous thromboembolic events in-hospital, and at 1, 3, 6, and 12 months after metabolic and bariatric surgery: systematic review of 87 studies and meta-analysis of 2,731,797 patients. Obes Surg. 2024;34(6):2154\u201376. https:\/\/doi.org\/10.1007\/s11695-024-07184-7.","journal-title":"Obes Surg"},{"issue":"5","key":"8882_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/MOH.0b013e3283634443","volume":"20","author":"IO Blokhin","year":"2013","unstructured":"Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20(5):437\u201344. https:\/\/doi.org\/10.1097\/MOH.0b013e3283634443.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"8882_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.17476\/jmbs.2025.14.2.131","volume":"14","author":"YJ Jung","year":"2025","unstructured":"Jung YJ. Obesity and venous thromboembolism: mechanisms, clinical implications, and prevention strategies with a focus on bariatric surgery. J Metab Bariatr Surg. 2025;14(2):131\u20138. https:\/\/doi.org\/10.17476\/jmbs.2025.14.2.131.","journal-title":"J Metab Bariatr Surg"},{"key":"8882_CR6","doi-asserted-by":"publisher","unstructured":"Zawadzka PS, Imiela AM, Pruszczyk P. The interplay between obesity and venous thromboembolism: from molecular aspects to clinical issue. Int J Mol Sci. 2025;26(21). https:\/\/doi.org\/10.3390\/ijms262110292.","DOI":"10.3390\/ijms262110292"},{"issue":"6","key":"8882_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1055\/s-0035-1556726","volume":"41","author":"MA Albayati","year":"2015","unstructured":"Albayati MA, Grover SP, Saha P, Lwaleed BA, Modarai B, Smith A. Postsurgical inflammation as a causative mechanism of venous thromboembolism. Semin Thromb Hemost. 2015;41(6):615\u201320. https:\/\/doi.org\/10.1055\/s-0035-1556726.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"8882_CR8","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1055\/a-2159-9957","volume":"7","author":"D Meknas","year":"2023","unstructured":"Meknas D, Br\u00e6kkan SK, Hansen JB, Morelli VM. Surgery as a trigger for incident venous thromboembolism: results from a population-based case-crossover study. TH Open. 2023;7(3):e244\u201350. https:\/\/doi.org\/10.1055\/a-2159-9957.","journal-title":"TH Open"},{"issue":"12","key":"8882_CR9","doi-asserted-by":"publisher","first-page":"e0145759","DOI":"10.1371\/journal.pone.0145759","volume":"10","author":"G Bouras","year":"2016","unstructured":"Bouras G, Burns EM, Howell A-M, Bottle A, Athanasiou T, Darzi A. Risk of post-discharge venous thromboembolism and associated mortality in general surgery: a population-based cohort study using linked hospital and primary care data in England. PLoS ONE. 2016;10(12):e0145759. https:\/\/doi.org\/10.1371\/journal.pone.0145759.","journal-title":"PLoS ONE"},{"issue":"2","key":"8882_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/8755122515617200","volume":"32","author":"MG Minze","year":"2016","unstructured":"Minze MG, Kwee YY, Hall RG. 2nd: low-molecular-weight heparin prophylaxis dosing: is weight an issue? J Pharm Technol. 2016;32(2):75\u201380. https:\/\/doi.org\/10.1177\/8755122515617200.","journal-title":"J Pharm Technol"},{"issue":"7","key":"8882_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/hq0701.093686","volume":"21","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of Action and Pharmacology of Unfractionated Heparin. Arterioscler Thromb Vasc Biol. 2001;21(7):1094\u20136. https:\/\/doi.org\/10.1161\/hq0701.093686.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"8882_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0889-8588(05)70052-6","volume":"12","author":"JN Huang","year":"1998","unstructured":"Huang JN, Shimamura A. Low-molecular-weight heparins. Hematol Oncol Clin N Am. 1998;12(6):1251\u201381. https:\/\/doi.org\/10.1016\/S0889-8588(05)70052-6.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"8882_CR13","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.4081\/hr.2019.7914","volume":"11","author":"DH Wiznia","year":"2019","unstructured":"Wiznia DH, Swami N, Nguyen J, Musonza E, Lynch C, Gibson D, Pelker R. Patient compliance with deep vein thrombosis prophylaxis after total hip and total knee arthroplasty. Hematol Rep. 2019;11(2):7914. https:\/\/doi.org\/10.4081\/hr.2019.7914.","journal-title":"Hematol Rep"},{"key":"8882_CR14","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/ecr.2021.55","volume":"17","author":"HN Tun","year":"2022","unstructured":"Tun HN, Kyaw MT, Rafflenbeul E, Su\u00e1stegui XL. Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis. Eur Cardiol. 2022;17:e11. https:\/\/doi.org\/10.15420\/ecr.2021.55.","journal-title":"Eur Cardiol"},{"issue":"6","key":"8882_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","volume":"127","author":"MM Samama","year":"2011","unstructured":"Samama MM. The mechanism of action of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor \u2013 compared with other anticoagulants. Thromb Res. 2011;127(6):497\u2013504. https:\/\/doi.org\/10.1016\/j.thromres.2010.09.008.","journal-title":"Thromb Res"},{"issue":"1","key":"8882_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s43162-023-00212-5","volume":"35","author":"S Wei","year":"2023","unstructured":"Wei S, Sawhney A, Khandait H, Meda A, Gupta V, Jain R. An update on applications and limitations of direct oral anticoagulants. Egypt J Intern Med. 2023;35(1):26. https:\/\/doi.org\/10.1186\/s43162-023-00212-5.","journal-title":"Egypt J Intern Med"},{"issue":"5","key":"8882_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","volume":"130","author":"KA Martin","year":"2017","unstructured":"Martin KA, Lee CR, Farrell TM, Moll S. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. Am J Med. 2017;130(5):517\u201324. https:\/\/doi.org\/10.1016\/j.amjmed.2016.12.033.","journal-title":"Am J Med"},{"key":"8882_CR18","doi-asserted-by":"publisher","first-page":"e070022","DOI":"10.1136\/bmj-2022-070022","volume":"378","author":"RJ Eck","year":"2022","unstructured":"Eck RJ, Elling T, Sutton AJ, Wetterslev J, Gluud C, van der Horst ICC, Gans ROB, Meijer K, Keus F. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ. 2022;378:e070022. https:\/\/doi.org\/10.1136\/bmj-2022-070022.","journal-title":"BMJ"},{"key":"8882_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.thromres.2024.01.007","volume":"235","author":"B Gunka","year":"2024","unstructured":"Gunka B, Mackenzie D, Hughes T, Sardo L, Bayadinova J, Siegal DM, Tseng EK, Doumouras AG, Mithoowani S. Pharmacokinetics of direct oral anticoagulants after bariatric surgery: A retrospective cohort study. Thromb Res. 2024;235:15\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2024.01.007.","journal-title":"Thromb Res"},{"key":"8882_CR20","doi-asserted-by":"crossref","unstructured":"Arcelus JI, Gouin-Thibault I, Samama CM. European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Chap. 10: Surgery in the obese patient. Eur J Anaesthesiol | EJA 2024;41(8).","DOI":"10.1097\/EJA.0000000000002000"},{"issue":"9","key":"8882_CR21","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jth.15823","volume":"20","author":"R Leong","year":"2022","unstructured":"Leong R, Chu DK, Crowther MA, Mithoowani S. Direct oral anticoagulants after bariatric surgery\u2014What is the evidence? J Thromb Haemost. 2022;20(9):1988\u20132000. https:\/\/doi.org\/10.1111\/jth.15823.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"8882_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/sla.0000000000001686","volume":"265","author":"A Aminian","year":"2017","unstructured":"Aminian A, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J, Brethauer SA, Schauer PR. Who should get extended thromboprophylaxis after bariatric surgery? a risk assessment tool to guide indications for post-discharge pharmacoprophylaxis. Ann Surg. 2017;265(1):143\u201350. https:\/\/doi.org\/10.1097\/sla.0000000000001686.","journal-title":"Ann Surg"},{"issue":"5","key":"8882_CR23","doi-asserted-by":"publisher","first-page":"e2315241","DOI":"10.1001\/jamanetworkopen.2023.15241","volume":"6","author":"D Kr\u00f6ll","year":"2023","unstructured":"Kr\u00f6ll D, Nett PC, Rommers N, Borb\u00e9ly Y, Deichsel F, Nocito A, Zehetner J, Kessler U, Fringeli Y, Alberio L, et al. Efficacy and safety of rivaroxaban for postoperative thromboprophylaxis in patients after bariatric surgery: a randomized clinical trial. JAMA Netw Open. 2023;6(5):e2315241\u20132315241. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15241.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"8882_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1308\/rcsann.2020.0209","volume":"102","author":"JI Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez JI, Kobus V, T\u00e9llez I, P\u00e9rez G. Prophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portomesenteric venous thrombosis. Ann R Coll Surg Engl. 2020;102(9):712\u20136. https:\/\/doi.org\/10.1308\/rcsann.2020.0209.","journal-title":"Ann R Coll Surg Engl"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08882-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-026-08882-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08882-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:54:33Z","timestamp":1789044873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-026-08882-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8882"],"URL":"https:\/\/doi.org\/10.1007\/s11695-026-08882-0","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Institutional Review Board. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}